	US 11,945,951 B2
	Formulation and its use as defoamer
Alexander Schulz, Essen (DE); Philippe Favresse, Ratingen (DE); Sascha Herrwerth, Freigericht (DE); Frank Schubert, Neukirchen-Vluyn (DE); Matthias Lobert, Essen (DE); Johannes Troendlin, Essen (DE); Thomas Thomalla, Essen (DE); Thorsten Schierle, Essen (DE); Michael Gippert, Essen (DE); and Jonas Urbath, Wuppertal (DE)
Assigned to Evonik Operations GmbH, Essen (DE)
Filed by Evonik Operations GmbH, Essen (DE)
Filed on Dec. 18, 2020, as Appl. No. 17/126,172.
Claims priority of application No. 20150732 (EP), filed on Jan. 8, 2020.
Prior Publication US 2021/0206972 A1, Jul. 8, 2021
Int. Cl. C08L 83/06 (2006.01); C08G 77/46 (2006.01); C08K 3/36 (2006.01); C09D 7/61 (2018.01); C09D 7/65 (2018.01); C09D 183/12 (2006.01)

CPC C08L 83/06 (2013.01) [C08G 77/46 (2013.01); C08K 3/36 (2013.01); C09D 7/61 (2018.01); C09D 7/65 (2018.01); C09D 183/12 (2013.01)]

17 Claims

1. A formulation, comprising a polyether siloxane, wherein a polyether that is terminated with an ester group and that is different from the polyether siloxane is present in the formulation in an amount of from 0.5 to 10% by weight based on the complete formulation,

wherein the polyether is polpropylene glycol monobutyl ether that is terminated with an ester group, wherein the ester group is selected from the group consisting of sulfate, phosphorylate, and maleate, and wherein the formulation is a defoamer formulation.